Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Evofem shares surge as contraceptive gel meets late-stage trial goal

December 17, 2018 3:42 PM
100 0

(Reuters) - Shares of Evofem Biosciences Inc jumped as much as 38 percent on Monday after its birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.

Male condoms and oral pills dominate the $5.5 billion contraceptive market in the United States. However, oral pills cause side effects such as bleeding between periods, mood swings and nausea in women.

Read more

Share in social networks:

Comments - 0